Q3 2026 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) achieved a milestone by closing a quarter with INR1,000 crores in revenue, marking an 8.1% growth on a standalone basis.
- The company reported a significant improvement in EBITDA margin, reaching 35.9%, which is a 520 basis point increase, driven by disciplined cost control and productivity improvements.
- The vaccines business, particularly Shingrix, showed strong growth, with Shingrix achieving an annual run rate of INR75 crores.
- The oncology portfolio, including the launch of Zejula and Jemperli, is expected to significantly contribute to future growth, with regulatory approvals expanding the eligible patient pool.
- The company is leveraging digital pathways and omnichannel strategies, achieving almost 4 million digital touchpoints with healthcare professionals in the quarter.
- The company faced supply constraints due to a fire at a contract manufacturing site, impacting sales by approximately INR25-30 crores.
- Despite the growth in specialty and vaccines, the general medicines segment, which constitutes a significant portion of revenue, experienced challenges in previous quarters.
- The impact of the National List of Essential Medicines (NLEM) continues to affect pricing and margins, with about 35-38% of the portfolio under price control.
- The launch of new specialty products involves higher costs, which could impact margins despite the potential for revenue growth.
- There is a risk of regulatory delays in India, which could affect the timing of new product launches compared to global markets.
Hi. Good evening, everyone. This is Darwin Daes, your moderator from Chorus Call. Welcome to the Glaxo Midline Pharmaceuticals Limited Q3 FY 2026 conference. From the management at GlaxoSmithKline Pharmaceuticals Limited, we have Mr. Bhushan Akshikar, Managing Director; and Mr. Juby Chandy, Chief Financial Officer.
By participating in this event, you consent to the recording, distribution and publication of this event. Kindly note that this call is meant for investors and analysts only. (Operator Instructions)
I now hand the conference over to Mr. Bhushan Akshikar. Thank you, and over to you, sir.
Thank you very much, Darwin. A very good evening to everyone. Thanks once again for joining us this evening for the Q3 conference call. Starting off from where we left last time when we announced the Q2 results, at GSK India, we continue to be anchored around the commercial ambition, which is around focus, innovation and agility. We continue to be a broadly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
